Expanding the Role of Oral Decitabine/Cedazurine Across MDS and CMML

Oral decitabine/cedazurine represents an important advancement in the management of both high-risk and select low-risk myelodysplastic syndromes (MDS), as well as chronic myelomonocytic leukemia (CMML). By combining decitabine with cedazurine, a cytidine deaminase inhibitor, this oral formulation achieves systemic exposure comparable to intravenous decitabine while offering greater convenience for patients. In higher-risk MDS and CMML, it provides a hypomethylating therapy option that maintains efficacy while reducing the logistical burden of frequent clinic visits. In lower-risk MDS, oral decitabine/cedazurine may be considered in carefully selected patients with progressive disease or those who have failed other therapies. Overall, its availability supports treatment individualization, improves patient quality of life, and has the potential to enhance adherence without compromising clinical outcomes.